Citadel Advisors
AXDX

Citadel Advisors’s Accelerate Diagnostics AXDX Stock Holding History

Citadel Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200
Closed -$140 – 12513
2025
Q1 		$140 Buy
+200
New +$228 ﹤0.01% 14322
2024
Q1 		– Sell
-400
Closed -$1.57K – 14535
2023
Q4 		$1.57K Buy
+400
New +$2.12K ﹤0.01% 13805
2023
Q3 		– Sell
-990
Closed -$8.02K – 14270
2023
Q2 		$8.02K Buy
990
+60
+6% +$451 ﹤0.01% 13343
2023
Q1 		$6.51K Sell
930
-3,850
-81% -$23.1K ﹤0.01% 13800
2022
Q4 		$33.7K Buy
4,780
+1,540
+48% +$16.8K ﹤0.01% 12605
2022
Q3 		$49K Sell
3,240
-65,450
-95% -$1.08M ﹤0.01% 11641
2022
Q2 		$682K Buy
68,690
+66,640
+3,251% +$589K ﹤0.01% 7932
2022
Q1 		$30K Sell
2,050
-1,530
-43% -$43.6K ﹤0.01% 13098
2021
Q4 		$187K Buy
3,580
+520
+17% +$28.9K ﹤0.01% 11946
2021
Q3 		$178K Buy
3,060
+710
+30% +$46.3K ﹤0.01% 12144
2021
Q2 		$189K Buy
2,350
+430
+22% +$34.2K ﹤0.01% 12221
2021
Q1 		$160K Sell
1,920
-270
-12% -$27.4K ﹤0.01% 11965
2020
Q4 		$166K Sell
2,190
-1,740
-44% -$156K ﹤0.01% 9878
2020
Q3 		$419K Sell
3,930
-2,000
-34% -$278K ﹤0.01% 7580
2020
Q2 		$899K Buy
5,930
+3,620
+157% +$357K ﹤0.01% 6022
2020
Q1 		$192K Sell
2,310
-1,560
-40% -$220K ﹤0.01% 8046
2019
Q4 		$654K Buy
3,870
+720
+23% +$119K ﹤0.01% 6360
2019
Q3 		$585K Sell
3,150
-690
-18% -$133K ﹤0.01% 6490
2019
Q2 		$879K Buy
3,840
+750
+24% +$147K ﹤0.01% 5904
2019
Q1 		$650K Sell
3,090
-2,940
-49% -$551K ﹤0.01% 6349
2018
Q4 		$693K Buy
6,030
+330
+6% +$48.9K ﹤0.01% 5893
2018
Q3 		$1.31M Sell
5,700
-1,180
-17% -$261K ﹤0.01% 5083
2018
Q2 		$1.53M Buy
6,880
+3,150
+84% +$705K ﹤0.01% 4504
2018
Q1 		$852K Sell
3,730
-360
-9% -$94.5K ﹤0.01% 5044
2017
Q4 		$1.07M Buy
4,090
+1,900
+87% +$445K ﹤0.01% 4562
2017
Q3 		$492K Buy
2,190
+540
+33% +$133K ﹤0.01% 5355
2017
Q2 		$451K Sell
1,650
-280
-15% -$75.9K ﹤0.01% 5266
2017
Q1 		$467K Buy
1,930
+590
+44% +$135K ﹤0.01% 5146
2016
Q4 		$278K Sell
1,340
-440
-25% -$104K ﹤0.01% 5790
2016
Q3 		$485K Sell
1,780
-380
-18% -$84.1K ﹤0.01% 4907
2016
Q2 		$311K Buy
2,160
+360
+20% +$48.3K ﹤0.01% 5156
2016
Q1 		$259K Buy
1,800
+830
+86% +$117K ﹤0.01% 5290
2015
Q4 		$208K Sell
970
-1,860
-66% -$339K ﹤0.01% 5755
2015
Q3 		$458K Buy
2,830
+2,070
+272% +$448K ﹤0.01% 4926
2015
Q2 		$196K Sell
760
-520
-41% -$124K ﹤0.01% 6349
2015
Q1 		$288K Buy
1,280
+320
+33% +$66.9K ﹤0.01% 5703
2014
Q4 		$184K Sell
960
-1,030
-52% -$220K ﹤0.01% 6068
2014
Q3 		$427K Buy
1,990
+160
+9% +$31.1K ﹤0.01% 4824
2014
Q2 		$476K Buy
+1,830
New +$399K ﹤0.01% 4462

Other funds holding AXDX

BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BCWM
Bartlett & Co Wealth Management Cincinnati, Ohio $7.82B AUM 15.4% 1-Year Est. Return

Citadel Advisors's AXDX Position: Q2 2025 in Review

Citadel Advisors sold out of Accelerate Diagnostics (AXDX) in Q2 2025, closing a stake of 23,451 shares — an estimated $16.4K sold.

Citadel Advisors first reported a position in AXDX in Q2 2014 and held it in 32 quarters. The position peaked at $2.38M in Q4 2019. 3 funds tracked by Wall St. Rank hold AXDX as of Q2 2025.

  • Citadel Advisors reported no remaining Accelerate Diagnostics position as of Q2 2025 after selling out during the quarter.
  • Citadel Advisors sold 23,451 Accelerate Diagnostics shares in Q2 2025, an estimated $16.4K.
  • Citadel Advisors first reported a position in Accelerate Diagnostics in Q2 2014 and held it in 32 quarters.
  • Citadel Advisors's Accelerate Diagnostics position peaked at $2.38M in Q4 2019.
  • 3 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.